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Abstract
Background: The Korean Registry of Target Organ Damage in Hypertension aims to evaluate the clinical
characteristics and prevalence of subclinical target organ damage in Korean hypertensive patients.
Method: This is a prospective, observational, multicenter cohort study in which 23 university hospitals participated.
Since May 2013, we have enrolled 1,318 consecutive hypertensive patients without known cardiovascular disease
who met the following inclusion criteria: 1) age older than 30 years and 2) the first visit to the participating
hospitals was within the last 5 years.
Results: The mean age was 52 ± 12 years; 62.1% were male, and 41.3% were incident hypertensives. Patients with
diabetes mellitus accounted for 7.8% of the population and 43.8% had hyperlipidemia or were on statins at
baseline. The mean office blood pressures were 152 ± 20/96 ± 14 mmHg for incident hypertensive patients and 129
± 13/78 ± 10 mmHg for patients on treatment. Patients with electrocardiographic and echocardiographic left
ventricular hypertrophy accounted for 18.9 and 25.6%, respectively. The mean brachial-ankle pulse wave velocity
(PWV) was 1564 ± 293 m/s and 19.5% had PWV values of more than 1750 cm/s. Patients with microalbuminuria and
chronic kidney disease accounted for 21 and 4%, respectively. The first prescribed class of antihypertensive
medications was angiotensin converting enzyme inhibitors in 2.9%, angiotensin receptor blockers (ARBs) in 57.5%,
diuretics in 7.6%, calcium channel blockers (CCBs) in 61.0%, beta blockers in 17.3%, and fixed dose combination pill
in 27.8%.
Conclusion: Our interim analysis shows that subclinical target organ damage in hypertension is considerably
present for incident or treated hypertensive patients. CCBs and ARBs were the most commonly prescribed classes
of antihypertensive medications and fixed dose combination pills were actively used in Korea.
Trial registration: NCT01861080. Registered 16 May 2013
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Background
Hypertension is an important worldwide public-health
challenge because of its high frequency and concomitant
risk of cardiovascular and kidney disease [1]. Substantial
evidence has established that lowering high blood pres-
sure (BP) is an effective way to prevent cardiovascular
and renal diseases [2]. Along with controlling BP, identi-
fication and treatment of other cardiovascular risk fac-
tors, such as hyperlipidemia, smoking, and diabetes
mellitus, is crucial in the management of hypertension.
Another important factors in the risk stratification and
management of hypertensive patients are the existence
of subclinical target organ damages (SODs) such as left
ventricular hypertrophy (LVH), carotid wall thickening,
increased pulsed wave velocity (PWV), chronic kidney
disease (CKD) with a reduced estimated glomerular fil-
tration rate (eGFR), and microalbuminuria (MAU) [3].
In the European hypertension guidelines, active search
for SODs is highly recommended because it allows a
better stratification of the cardiovascular risk and helps
physicians select the most appropriate antihypertensive
medicines [3].
Despite the emphasis of guidelines on active investiga-
tion for SOD, large-population based data are limited in
terms of the prevalence of SODs in Korean hyperten-
sives. Therefore, we aimed to determine the prevalence
of SODs and distinct characteristics in Korean hyperten-
sives by constructing a nationwide hypertension registry.
Hereafter, we report the study design and interim ana-




The KorHR is a prospective, observational, multicenter
cohort study in which 24 university hospitals in the Re-
public of Korea participated. From May 2013, patients
were consecutively enrolled if they 1) were older than
30 years old, 2) had primary hypertension, and 3) con-
sented to registry enrollment. Study patients were classi-
fied into one of two tracks. One is a group of patients
who were diagnosed with primary hypertension at en-
rollment and had never taken an antihypertensive medi-
cation (incident group). Patients were also considered as
the incident group if they had been diagnosed with pri-
mary hypertension before enrollment and had not taken
antihypertensive medications for more than 2 weeks
from the time of enrollment. The second is a group of
patients who had taken antihypertensive treatment be-
fore the study enrollment and first visited research insti-
tutions within the past 5 years (on-treatment group).
We excluded patients with obvious cardiovascular dis-
ease at baseline, such as cerebrovascular disease,
coronary artery disease, heart failure, peripheral artery
disease, and CKD with an eGFR of less than 30 mL/min/
1.73 m2.
At the baseline visit, the demographic and anthropo-
metric characteristics of eligible patients were recorded
and the medical history, such as diabetes mellitus (DM),
hyperlipidemia, regular exercise, and smoking were also
reported. DM was defined as fasting plasma glucose ≥
126 mg/dL or hemoglobin A1c ≥ 6.5% or if patient were
taking anti-diabetic medications. Hyperlipidemia was de-
fined as total cholesterol ≥ 240 mg/dL or low density
lipoprotein ≥ 160 mg/dL or triglyceride ≥ 200 mg/dL or if
patients were taking statins. Regular exercise was defined
if patients do exercise (aerobic or anaerobic) for more
than 30 min at a time and at least three times a week.
The systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured two or three times in
both arms at intervals of 3 min in accordance with the
official recommendations for BP measurements [4]. The
mean values of each measurement was recorded as the
office BPs. Ambulatory BP monitoring was also used to
rule out patients with white coat hypertension and
evaluate the BP status. Laboratory tests were performed,
including simple urinalysis, complete blood count,
serum chemistry, serum lipid, serum uric acid, plasma
renin activity, and aldosterone. The SODs of hyperten-
sion such as LVH, MAU, CKD, and increased PWV,
were thoroughly scrutinized.
Finally, we investigated each class of antihypertensive
medication that was prescribed first and analyzed a
trend of antihypertensive treatment with medicines. We
aimed to evaluate the cardiovascular outcomes for up to
5 years, including all cause death, cardiovascular death,
ischemic or hemorrhagic stroke, myocardial infarction,
coronary revascularization, and heart failure, although
we do not report on the cardiovascular outcomes in this
interim analysis.
Definitions of the primary outcome
The primary outcome was the presence of SODs of
hypertension, such as LVH, increased PWV, CKD with
an eGFR of 30–60 mL/min/1.73 m2, and MAU. Electro-
cardiographic LVH was defined by the modified
Sokolow-Lyon index (largest S-wave + largest R-wave >
3.5 mV) and the assessment of echocardiographic LVH
was based on the criteria proposed by the European
hypertension guidelines [left ventricular mass index:
men >115 g/m2 and women >95 g/m2 (BSA)] [3]. Left
ventricular mass was calculated according to linear
method using the following equation [5].
Left ventricular mass = 0.8 * 1.04 * [(thickness of inter-
ventricular septum at diastole + left ventricular internal
diameter at diastole + posterior wall thickness at
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diastole)3 – (left ventricular internal dimension at dia-
stole)3] + 0.6 g.
The calculation of relative wall thickness (RWT) by
the formula [(2*posterior wall thickness at diastole)/left
ventricular internal dimension at diastole] permits the
categorization of LVH as either concentric (RWT > 0.42)
or eccentric (RWT ≤ 0.42) [5]. MAU was defined as a
urine albumin/creatinine ratio (ACR) in spot urine of
≥30 mg/g but <300 mg/g [6]. Individuals with an eGFR ≤
60 mL/min per 1.73 m2 are defined as having CKD ac-
cording to the K/DOQI clinical practice guidelines for
CKD [7]. We calculated the eGFR using the Modifica-
tion of Diet in Renal Disease Study equation [8]. The
brachial-ankle pulse wave velocity (baPWV) was mea-
sured with the individuals in a supine position after at
least 5 min of rest. Pressure waveforms of the brachial
and tibial arteries were simultaneously recorded by pla-
cing occlusion cuffs connected to a plethysmographic
sensor around both the brachia and ankles. The time de-
lays (T) of the two waveforms between one foot and the
other were measured. The lengths of the paths from the
suprasternal notch to the brachium (Lb) and from the
suprasternal notch to the ankle (La) were automatically
calculated according to the height of each individual.





A threshold of >1,750 cm/s for the baPWV was deter-
mined for the presence of SOD, which was the cut-off
value of baPWV for predicting cardiovascular disease in
previous studies [9, 10].
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation (SD) and were compared using the t
test or Wilcoxon’s rank-sum test. Categorical data were
expressed as frequencies and percentages, and they were
compared using the χ2 test or Fisher’s exact test. Con-
tinuous variables were compared using the student’s t
test or by the nonparametric Mann-Whitney U test. For
all tests, a probability value of p <0.05 was considered
significant. All statistical analyses were performed using
statistical software SPSS (Chicago, Illinois) version 19.0.
Results
As of April 2016, a total of 1,318 patients with primary
hypertension had been enrolled in the KorHR registry.
Of 1,318 eligible patients, 611 patients (46%) were in-
cluded in the incident group and the remaining 707 pa-
tients (54%) were in the on-treatment group.
Demographic and anthropometric characteristics of the
patients are described in Table 1. In short, the mean age
of all patients was 51 years and 60% of the patients were
male. Patients with obesity (BMI ≥25 kg/m2) accounted
for 57.5%. Hyperlipidemia (43.8%) was the most com-
mon comorbidity. The mean overall office BP was 140 ±
20/86 ± 15 mmHg. Among patients in the on-treatments
group, 534 (75.5%) subjects had a BP that was lower
than 140/90 mmHg. Table 2 shows the baseline labora-
tory data. Approximately 60% of study patients had im-
paired fasting glucose (fasting glucose more than
100 mg/dL but less than 126 mg/dL). The average eGFR
was 89 ± 20 ml/min/1.73 m2 (BSA) and mean LDL was
114 ± 33 mg/dl. The mean baPWV was 1558 ± 285 cm/s
in all patients. In Fig. 1, 24-hour ambulatory BP moni-
toring is shown. Of 1,318 patients, 711 performed 24-
hour ambulatory BP monitoring. The mean 24-hour SBP
and DBP were 138 and 91 mmHg, respectively.
The prevalence of SODs, which is the primary end-
point of this study, is shown in Fig. 2. Echocardiography
was performed in 524 patients and 1,088 patients under-
went electrocardiography. The prevalence of echocardio-
graphic and electrocardiographic LVH were 25.6 and
18.9% in all patients, respectively. When comparing the
incident group with the on-treatment group, although
the overall echocardiographic LVH seemed to be more
prevalent in the on-treatment group (28.8 vs. 22.8%, p =
0.132), it was not statistically significant (Table 3). In
terms of hypertensive ventricular remodeling, eccentric
LVH was significantly more frequent in the on-
treatment group than the incident group (18.9 vs. 10.0%,
p = 0.004). However, electrocardiographic LVH was sig-
nificantly more frequent in the incident group than the
on-treatment group (22.8 vs. 14.9%, p = 0.015). The test
of MAU using ACR was performed in 940 patients.
Among them, 179 patients (19.0%) had MAU and 26 pa-
tients (2.1%) had overt proteinuria. The value of the
eGFR could be obtained in 1,161 patients and the preva-
lence of CKD, which was defined as an eGFR 30–60 ml/
min/1.73 m2 (BSA), was 4%. When we set the cut-off
value of baPWV to 1,750 m/s, the prevalence of an in-
creased PWV was 19.5%.
The class of antihypertensive medicines prescribed at
baseline was investigated. The most frequently pre-
scribed class was calcium channel blockers (CCBs)
(61%), which was followed by angiotensin receptor
blockers (ARBs) (57.5%), beta blockers (17.6%), diuretics
(7.6%), and angiotensin converting enzyme (ACE) inhibi-
tors (2.9%). Among them, 27.8% were prescribed with a
fixed dose combination pill; most of these combination
pills were an ARB plus CCB (83.6%).
Discussion
This study shows the integrated prevalence of SODs for
primary hypertension in hypertensive patients in Korea.
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SODs in primary hypertension were quite prevalent:
18.9% for ECG LVH, 25.6% for echo LVH, 19% for
MAU, and 19.5% for increased PWV.
With respect to the LVH, eccentric LVH (14.1%) was
slightly more frequent than concentric LVH (11.5%) in
all subjects. Notably, although concentric LVH seemed
to be more common in the incident group than in the
on-treatment group, albeit not statistically significant,
eccentric LVH was significantly more frequent in the
on-treatment group than in the incident group. This
finding is consistent with previous studies, including a
recent systemic review on echocardiographic LVH [11,
Table 1 Baseline characteristics
Overall (N = 1,318) Incident (N = 611) On treatment (N = 707)
Age, years ± SD 52 ± 12 47 ± 11 56 ± 11
Males (%) 818 (62.1) 415 (67.9) 403 (57.0)
BMIa (kg/m2) ± SDb 25.9 ± 3.5 26.2 ± 3.6 25.8 ± 3.4
Obesityc (%) 56.8 61.2 52.8
Waist (cm) ± SD 88 ± 9 89.7 ± 8.8 87 ± 9
Office SBP (mmHg) ± SD 140 ± 20 152 ± 20 129 ± 13
Office DBP (mmHg) ± SD 86 ± 15 96 ± 14 78 ± 10
Office HR (beats per minute) ± SD 75 ± 18 77 ± 12 72 ± 11
Hypertension awareness (months) 48 ± 65 22 ± 40 71 ± 74
Diabetes mellitus (%) 7.8 3.9 11.0
Hyperlipidemia (%) 43.8 35.1 51.0
Regular exercise (%) 32.3 28.8 39.8
Smoking (%)
Never 54.8 51.5 57.4
Past 19.4 15.1 22.8
Current 20.2 25.6 15.8
aBMI body mass index; bSD standard deviation; cObesity defined as a BMI ≥25 kg/m2
Table 2 Laboratory Data
Overall (N = 1,318) Incident (N = 611) On treatment (N = 707)
Hemoglobin (g/dL) 14.6 ± 3.5 14.9 ± 1.6 14.4 ± 4.6
Hematocrit (%) 43.0 ± 4.5 44.0 ± 4.8 42.1 ± 3.9
Glucose (mg/dL) 108 ± 25 106 ± 24 109 ± 26
Impaired fasting glucose (%) 59.8 56.0 63.0
Total cholesterol (mg/dL) 188 ± 36 200 ± 36 177 ± 32
Triglyceride (mg/dL) 151 ± 109 166 ± 128 139 ± 87
HDL (mg/dL) 52 ± 14 51 ± 15 52 ± 13
LDL (mg/dL) 114 ± 33 127 ± 32 104 ± 31
Uric acid (mg/dL) 5.5 ± 2.4 5.8 ± 3.2 5.3 ± 1.4
Estimated GFR (mL/min/1.73 m2) 89 ± 20 93 ± 26 87 ± 21
Urine albumin creatinine ratio (mg/g),
median (1/4 quartile, 3/4 quartile)
10.3 (4.9, 24.8) 10.5 (5.0, 23.7) 10.1 (4.8, 25.5)
Renin (ng/ml/h) 3.35 ± 6.75 3.12 ± 6.76 4.16 ± 6.71
Aldosterone (pg/mL) 9.8 ± 7.5 9.6 ± 6.5 10.42 ± 10.05
PWVa 1558 ± 285 1569 ± 289 1543 ± 278
Central SBP 133 ± 20 136 ± 19 130 ± 21
Central DBP 88 ± 13 92 ± 12 83 ± 12
Augmentation index 38 ± 27 33 ± 24 47 ± 28
a PWV pulsed wave velocity
Choi et al. Clinical Hypertension  (2017) 23:16 Page 4 of 7
12]. Mancia et al. reported that eccentric LVH was more
frequent than concentric LVH and the change in the left
ventricular geometry due to high BP was retained re-
gardless of whether the BP was normal or elevated and
whether treatment did or did not achieve BP control
[11]. As mentioned above, approximately 75% of patients
in the on-treatment group in this study achieved target
BP. As they proposed, the persistence of cardiac struc-
ture abnormalities such as LVH may not completely re-
gress even after achieving target BPs. Additionally, the
structural geometry may change with treatment, i.e.,
from concentric LVH to eccentric LVH with alteration
of the RAS system. Concentric LVH was associated with
a worse prognosis than the eccentric LVH [13]. How-
ever, eccentric LVH was also a significant predictor of
the development of low LVEF. [14] Therefore, this result
showed that even incident hypertensive patients are ex-
posed to a risk of cardiovascular diseases in addition to
patients on hypertensive treatment regardless of whether
they achieved target BP. In contrast to echocardio-
graphic LVH, electrocardiographic LVH was more
prevalent in the incident group than in the on-treatment
group. This finding can be explained that electrocardio-
graphic change due to LVH and BP control might occur
more easily than an echocardiographic left ventricular
mass change.
MAU is known to be the integrated marker of SODs
in primary hypertension [15]. MAU is associated with
metabolic derangements and an increased cardiovascular
risk in hypertension patients [16, 17]. The previously re-
ported prevalence of MAU varies from 4.7 to 40% ac-
cording to study populations [18–23]. Among them, the
I-DEMAND (Italy Developing Education and awareness
on Microalbuminuria in hypertensive Disease) study,
which enrolled patients with similar characteristics as
this study, showed that the overall prevalence of MAU
was 27% in 3,534 hypertensive patients [19]. Two previ-
ous Korean studies showed that the prevalence of MAU
were 5.4 and 10.1%, which included patients who visited
primary clinics or participated in the health examination
program [22, 23]. Several factors are known for affecting
the prevalence of MAU. MAU is more frequent in
Fig. 1 Values of Twenty-four hour ambulatory blood pressure monitoring. 24 h, 24 h average; SBP, systolic blood pressure; DBP, diastolic blood
pressure; Day, awake time average; Night, sleep time average
Fig. 2 Prevalence of subclinical target organ damage. SOD, subclinical organ damage; Echo LVH, echocardiographic left ventricular hypertrophy;
ECG LVH, electrocardiographic left ventricular hypertrophy; MAU, microalbuminuria; CKD, chronic kidney disease; PWV, pulse wave velocity
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patients with high stages of hypertension [24]. In
addition to the severity of hypertension, age, sex, obesity,
and concomitant risk factors could influence the pres-
ence of MAU, although other studies report conflicting
results [20, 25–27]. The difference between the present
study and other Korean studies is mainly due to the
characteristics of patients who visited different clinical
settings, such as primary clinics and referral hyperten-
sion specialized clinics. The result suggests that MAU is
significantly prevalent in Korean hypertensive patients
and active investigation for MAU is encouraged for all
hypertensive patients, as recommended by the guide-
lines. Although the prevalence of asymptomatic CKD
was rare in incident hypertensives (2.4%), it rose to a
considerable level (5.3%) in patients who have been
treated with antihypertensive medicines for up to
5 years.
The carotid-femoral PWV (cfPWV) has been acknowl-
edged as the standard of arterial stiffness [28]. However,
the baPWV, which is much easier to measure, is more
available in South Korea. Previous reports have shown
that baPWV was correlated well with cfPWV and pre-
dicted worse outcomes in hypertensive patients [29, 30].
These studies suggest that the baPWV cut-off value was
approximately 1750 cm/s, which was associated with in-
creased cardiovascular events and mortality [9, 10, 31,
32]. In this study, an overall prevalence of baPWV of
more than 1750 cm/s was 11.9%. The prevalence of in-
creased baPWV was significantly higher in the incident
group than in the on-treatment group (16.0% vs. 8.3%, p
< 0.001), which could probably be affected by the high
BP status of the incident group.
This study has limitations. First, we enrolled patients
who visited hypertension specialized clinics in university
hospitals. Because these patients could not be extrapo-
lated to general population with hypertension, the preva-
lence of SODs could be exaggerated. Second, the
performance rate of ECG, MAU, PWV, and 2D echocar-
diography was 82, 71, 61 and, 40%. Therefore, the find-
ings of 2D echocardiography could be skewed. However,
the prevalence of each SOD was quite comparable to
previous studies.
Finally, our analysis of antihypertensive medicines
demonstrated that CCBs and ARBs are the most com-
monly prescribed antihypertensive medicines. Notably,
ACE inhibitors were rarely prescribed, which is probably
due to the high incidence of ACE inhibitor-induced
cough in Asians [33]. Furthermore, fixed dose combin-
ation pills, which are expected to improve drug compli-
ance, are actively used in South Korea. [34] In South
Korea, there is no commercially available fixed dose
combination pill that incorporates both an ACE inhibi-
tor and CCB, which could explain the high rate of ARB
uses.
Conclusions
Interim analysis of the KorHR study showed that SODs
of hypertension were prevalent in both incident and on-
treatment hypertensive patients. In terms of medicines,
CCBs and ARBs were the most commonly prescribed
classes of antihypertensive medications and fixed dose
combination pills are actively used in South Korea.
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Table 3 Echocardiographic left ventricular hypertrophy
Overall (N = 524) Incident (N = 281) On treatment (N = 243) p value
LVH 25.6 22.8 28.8 0.132
Concentric LVH (%) 11.5 12.8 9.9 0.336
Eccentric LVH (%) 14.1 10.0 18.9 0.004
Concentric remodeling (%) 12.2 12.1 12.3 0.932
Normal (%) 62.2 65.1 58.8 0.149
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